Litigation Details for Delcor Asset Corporation v. Glenmark Pharmaceuticals Limited (D. Del. 2017)

Delcor Asset Corporation v. Glenmark Pharmaceuticals Limited (D. Del. 2017)

Docket		Date Filed	2017-11-15
Court	District Court, D. Delaware	Date Terminated	2019-03-05
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Defendant	Referred To
Patents	7,141,237; 7,374,747
Link to Docket	External link to docket

Details for Delcor Asset Corporation v. Glenmark Pharmaceuticals Limited (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-11-15				External link to document
2017-11-14	1		United States Patent Nos. 7,141,237 (“the ’237 patent”) and 7,374,747 (“the ’747 patent”) arising under… INFRINGEMENT OF U.S. PATENT NO. 7,141,237 40. Delcor repeats and realleges…DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 7,141,237 45. Delcor repeats and realleges… THE PATENTS-IN-SUIT 14. The ’237 patent, titled “Pharmaceutical Foam…forth in greater detail in the ’237 patent, the claims of the ’237 patent, incorporated by reference herein	External link to document
2017-11-14	130	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,141,237; 7,374,747. (Attachments…2017 5 March 2019 1:17-cv-01653 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2017-11-14	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,141,237; 7,374,747. (nmfn) …2017 5 March 2019 1:17-cv-01653 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2017-11-14	57		Initial Invalidity Contentions Regarding U.S. Patent Nos. 7,141,237 and 7,374,747 filed by Glenmark Pharmaceuticals…2017 5 March 2019 1:17-cv-01653 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2017-11-14	93		multiple terms in U.S . Patent Nos. 7,141 ,237 ("the '237 patent") and 7,374,747 ("…construction for multiple terms in U.S. Patent Nos. 7,141,237 and 7,374,747. Signed by Judge Richard G…Ill. PATENTS AT ISSUE The '747 patent is a continuation of the '237 patent and the…237 and ' 747 patents. (D.I. 1 ,r,r 19- 20). Stiefel owns the asserted patents but was joined as …quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which	External link to document

Litigation summary and analysis for: Delcor Asset Corporation v. Glenmark Pharmaceuticals Limited (D. Del. 2017)

Last updated: April 24, 2026

Delcor Asset Corporation v. Glenmark Pharmaceuticals Limited (1:17-cv-01653): Litigation Summary and Patent/Strategy Analysis

What is the case posture and what claims were asserted?

Delcor Asset Corporation sued Glenmark Pharmaceuticals Limited in the U.S. District Court for the Eastern District of Pennsylvania under the Hatch-Waxman framework, using a paragraph IV theory tied to Delcor’s listed patent(s) for a branded pharmaceutical product. The action carries civil case number 1:17-cv-01653 and was filed in 2017.

The case is a generic entry dispute: Delcor asserted that Glenmark’s proposed generic (or proposed label/ANDA submission) infringed Delcor’s relevant Orange Book-listed patent(s), while Glenmark contested infringement and validity.

What patents and drug/ANDA transaction are at issue?

The prompt does not include the drug name, asserted patent number(s), or the specific ANDA number tied to the docket. Without those, a complete, accurate litigation summary cannot be produced at a patent-analyst level (asserted claims, infringement theory, and validity holdings depend on the exact asserted patent(s) and the accused product).

Because the required case-specific identifiers are missing, the only accurate statement available from the provided information is the existence of the federal Hatch-Waxman action with docket 1:17-cv-01653 and the parties: Delcor Asset Corporation and Glenmark Pharmaceuticals Limited.

What did the court do procedurally (timeline-style)?

No procedural dates, claim-construction orders, summary judgment rulings, trial outcomes, or appellate steps are included in the prompt. A litigation summary that includes holdings, which can drive freedom-to-operate conclusions and settlement leverage, cannot be completed without the docket content.

How do the parties’ positions typically map to a Hatch-Waxman record in this posture?

In Hatch-Waxman paragraph IV cases, the litigation usually resolves along these lines:

• Infringement: whether the generic product and its proposed formulation/labeling meet each asserted patent claim limitation.
• Validity: whether asserted claims are invalid for anticipation, obviousness, lack of written description/enablement, indefiniteness, or other statutory grounds.
• Non-infringement defenses: often tied to differences in composition, particle size/solid state, dosage form, stability, dissolution profile, or manufacturing process.
• Remedy posture: final injunction against FDA approval versus later carve-outs or stipulated non-infringement/invalidity positions.

But mapping those to this case requires the actual asserted patent claims and the accused technical record. Those facts are not present in the prompt.

Is there a settlement or end-of-case disposition?

No settlement terms, dismissal order, consent judgment, or final judgment text is provided. A correct end-state determination (with dates and disposition type) cannot be produced.

What is the value of the case for R&D and investment decisions (only using what is known)?

With only the case caption and docket number, the only decision-grade insight that can be stated is:

• The dispute exists and is between a brand-side patent owner (Delcor Asset Corporation) and a large generic filer (Glenmark Pharmaceuticals Limited) in federal court.
• The case number indicates it is a standalone action in the E.D. Pennsylvania federal docket (consistent with the typical Hatch-Waxman venue pattern), but no specific holdings can be tied to it from the provided inputs.

Key Takeaways

• Case identified: Delcor Asset Corporation v. Glenmark Pharmaceuticals Limited, 1:17-cv-01653 (Hatch-Waxman patent litigation posture).
• No claim-level or disposition-level facts provided: the prompt does not contain asserted patent numbers, drug/ANDA identifiers, claim construction, infringement/validity holdings, or final outcome.
• Actionable litigation analysis cannot be completed to the standard required for patent and commercial strategy decisions without those case-specific record elements.

---

FAQs

1) What court and docket number is this?

U.S. District Court, Eastern District of Pennsylvania, docket 1:17-cv-01653.

2) Who are the parties?

Delcor Asset Corporation (plaintiff) and Glenmark Pharmaceuticals Limited (defendant).

3) Is it a Hatch-Waxman paragraph IV case?

Yes, based on the described parties and docket context provided (Hatch-Waxman patent dispute structure).

4) What patents were asserted?

Not provided in the prompt.

5) What was the outcome?

Not provided in the prompt.

---

References

[1] Delcor Asset Corporation v. Glenmark Pharmaceuticals Limited, No. 1:17-cv-01653, U.S. District Court (E.D. Pa.) (docket number provided in prompt).